Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acthar Gel 14 Days vs 5 Days for MS Exacerbations
NCT01888354Phase 4Completed
- Sponsor
- UTHealth Houston
- Start
- Apr 2013
- Primary completion
- Aug 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of repository corticotropin injection in multiple sclerosis (MS) (2 arms), sponsored by UTHealth Houston. Primary endpoint: Expanded Disability Status Scale Mean Recovery at 90 days. Started Apr 2013; status: completed.
02
Drugs
repository corticotropin injection
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT01888354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01888354.